Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.

Novo Nordisk is repriced as if its fundamentals have sharply deteriorated, despite strong underlying demand. Learn why NVO stock is rated a buy.

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year to $675 a month, the Danish ...

Shares of Novo Nordisk (NVO 0.29%) sank 20% this week, according to data from S&P Global Market Intelligence. The drugmaker ...

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.

Novo Nordisk is deeply undervalued, trading at distressed multiples despite a robust pipeline and strong financials. Learn ...

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...

Novo Nordisk struck a licensing deal valued at up to $2.1 billion to gain access to oral drug-delivery technologies developed by U.S. startup Vivtex, as the Danish drugmaker moves to deepen its ...

Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral obesity and diabetes drugs.

Vivtex Corporation, launched in 2018 as a spinoff of the Massachusetts Institute of Technology (MIT), will license oral drug-delivery technologies to Novo for weight loss, diabetes, and related ...